A large body of preclinical research has confirmed that in experimental stroke models, VNS can significantly reduce infarct volume, lower the levels of pro-inflammatory cytokines (e.g., TNF-α, IL-6) in serum and brain tissue, and improve neurological outcomes (127). The gene discussed is TNF; the disease is stroke disorder.